BC
NBIX icon

Bayforest Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bayforest Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Sell
140
-841
-86% -$125K 0.02% 763
2026
Q1 		$129K Sell
981
-982
-50% -$130K 0.14% 277
2025
Q4 		$278K Sell
1,963
-217
-10% -$31.4K 0.21% 170
2025
Q3 		$306K Buy
+2,180
New +$295K 0.15% 284

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bayforest Capital's NBIX Position: Q2 2026 in Review

Bayforest Capital reduced its Neurocrine Biosciences (NBIX) stake by 86% in Q2 2026, selling an estimated $125K and leaving 140 shares worth $23.6K. The position accounts for 0.02% of the portfolio, ranked #763.

Bayforest Capital first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $306K in Q3 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bayforest Capital held 140 shares of Neurocrine Biosciences worth $23.6K as of Q2 2026.
  • Bayforest Capital sold 841 Neurocrine Biosciences shares in Q2 2026, an estimated $125K.
  • Neurocrine Biosciences made up 0.02% of Bayforest Capital's portfolio in Q2 2026, its #763 holding.
  • Bayforest Capital first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Bayforest Capital's Neurocrine Biosciences position peaked at $306K in Q3 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.